Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
ExteNET study explored neratinib prolong anti-HER2 therapy after trastuzumab therapy found
that it can improve disease-free survival in patients with lymph nodes positive; In addition,
the subgroup of patients with residual tumors after neoadjuvant therapy was found to improve
the survival. However, no conclusive conclusions were reached.
However, since the study was carried out early so only trastuzumab treatment was used, it is
urgent to carry out research that is more in line with current clinical practice and bring
more benefits to patients. To explore whether pyrotinib can further reduce the risk of
recurrence from previously diagnosed HER2-positive breast cancer after treatment with
trastuzumab and pertuzumab or T-DM1.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University